Eli Lilly: completes acquisition of ARMO BioSciences
(CercleFinance.com) - Eli Lilly has completed the acquisition of immuno-oncology company ARMO BioSciences, the US drugmaker said on Friday.
Lilly's tender offer for all ARMO's outstanding common stock, at a price of 50 dollars per share in cash, expired as scheduled yesterday, the company said.
At the expiry of the offer, approximately 90.6% of ARMO's shares had been validly tendered, Lilly said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Lilly's tender offer for all ARMO's outstanding common stock, at a price of 50 dollars per share in cash, expired as scheduled yesterday, the company said.
At the expiry of the offer, approximately 90.6% of ARMO's shares had been validly tendered, Lilly said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.